Veeva Systems (VEEV) 10-Q 7 Dec 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Oct. 31, 2022	Nov. 30, 2022
Document And Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 31, 2022
Document Transition Report	false
Entity File Number	001-36121
Entity Registrant Name	Veeva Systems Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8235463
Entity Address, Address Line One	4280 Hacienda Drive
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	452-6500
Title of 12(b) Security	Class A Common Stock,par value $0.00001 per share
Trading Symbol	VEEV
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001393052
Current Fiscal Year End Date	--01-31
Class A common stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		140,923,128
Class B common stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		14,765,331

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Current assets:
Cash and cash equivalents	$ 865,159	$ 1,138,040
Short-term investments	2,157,396	1,238,064
Accounts receivable, net of allowance for doubtful accounts of $1,442 and $473, respectively	242,859	631,134
Unbilled accounts receivable	82,085	63,266
Prepaid expenses and other current assets	38,986	36,679
Total current assets	3,386,485	3,107,183
Property and equipment, net	51,135	54,495
Deferred costs, net	27,875	33,106
Lease right-of-use assets	57,249	49,640
Goodwill	439,877	439,877
Intangible assets, net	87,382	101,940
Deferred income taxes	98,573	5,097
Other long-term assets	34,141	25,127
Total assets	4,182,717	3,816,465
Current liabilities:
Accounts payable	40,926	20,348
Accrued compensation and benefits	40,265	33,834
Accrued expenses and other current liabilities	32,860	36,109
Income tax payable	54,466	7,761
Deferred revenue	510,098	731,746
Lease liabilities	11,665	10,981
Total current liabilities	690,280	840,779
Deferred income taxes	1,546	2,216
Lease liabilities, noncurrent	50,225	43,607
Other long-term liabilities	21,874	18,226
Total liabilities	763,925	904,828
Commitments and contingencies (note 13)
Stockholders’ equity:
Additional paid-in capital	1,438,213	1,196,547
Accumulated other comprehensive loss	(45,642)	(11,958)
Retained earnings	2,026,219	1,727,046
Total stockholders’ equity	3,418,792	2,911,637
Total liabilities and stockholders’ equity	4,182,717	3,816,465
Class A common stock
Stockholders’ equity:
Common stock	2	2
Class B common stock
Stockholders’ equity:
Common stock	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Allowance for doubtful accounts	$ 1,442	$ 473
Class A common stock
Common stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	800,000,000	800,000,000
Common stock, shares issued (in shares)	140,866,593	139,432,822
Common stock, shares outstanding (in shares)	140,866,593	139,432,822
Class B common stock
Common stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	190,000,000	190,000,000
Common stock, shares issued (in shares)	14,765,431	14,763,775
Common stock, shares outstanding (in shares)	14,765,431	14,763,775

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Revenues:
Total revenues		$ 552,351	$ 476,111	$ 1,591,671	$ 1,365,278
Cost of revenues:
Total cost of revenues	[1]	153,907	129,564	445,091	367,797
Gross profit		398,444	346,547	1,146,580	997,481
Operating expenses:
Research and development	[1]	130,257	98,635	377,740	276,760
Sales and marketing	[1]	93,910	72,423	259,642	208,822
General and administrative	[1]	52,873	42,781	159,030	126,121
Total operating expenses	[1]	277,040	213,839	796,412	611,703
Operating income		121,404	132,708	350,168	385,778
Other income, net		12,458	824	23,565	7,054
Income before income taxes		133,862	133,532	373,733	392,832
Provision for income taxes		25,405	27,663	74,560	62,538
Net income		$ 108,457	$ 105,869	$ 299,173	$ 330,294
Net income per share:
Basic (in usd per share)		$ 0.70	$ 0.69	$ 1.93	$ 2.16
Diluted (in usd per share)		$ 0.67	$ 0.65	$ 1.84	$ 2.03
Weighted-average shares used to compute net income per share:
Basic (in shares)		155,392	153,514	154,958	153,020
Diluted (in shares)		162,295	163,034	162,189	162,663
Other comprehensive income:
Net change in unrealized loss on available-for-sale investments		$ (17,499)	$ (2,741)	$ (30,722)	$ (4,044)
Net change in cumulative foreign currency translation loss		(808)	(308)	(2,962)	(2,686)
Comprehensive income		90,150	102,820	265,489	323,564
Subscription services
Revenues:
Total revenues		441,569	380,738	1,272,850	1,088,293
Cost of revenues:
Total cost of revenues	[1]	65,734	59,648	188,722	164,774
Professional services and other
Revenues:
Total revenues		110,782	95,373	318,821	276,985
Cost of revenues:
Total cost of revenues	[1]	$ 88,173	$ 69,916	$ 256,369	$ 203,023
[1] (1) Includes stock-based compensation as follows: Cost of revenues: Cost of subscription services $ 1,636 $ 1,292 $ 4,606 $ 3,514 Cost of professional services and other 13,227 9,616 37,035 26,579 Research and development 37,415 22,311 102,139 61,463 Sales and marketing 23,576 15,102 64,500 41,772 General and administrative 17,333 13,724 48,083 39,591 Total stock-based compensation $ 93,187 $ 62,045 $ 256,363 $ 172,919

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Total stock-based compensation	$ 93,187	$ 62,045	$ 256,363	$ 172,919
Cost of subscription services
Total stock-based compensation	1,636	1,292	4,606	3,514
Cost of professional services and other
Total stock-based compensation	13,227	9,616	37,035	26,579
Research and development
Total stock-based compensation	37,415	22,311	102,139	61,463
Sales and marketing
Total stock-based compensation	23,576	15,102	64,500	41,772
General and administrative
Total stock-based compensation	$ 17,333	$ 13,724	$ 48,083	$ 39,591

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Class A & B common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss
Beginning balance (in shares) at Jan. 31, 2021		152,056,808
Beginning balance at Jan. 31, 2021	$ 2,266,320	$ 2	$ 965,670	$ 1,299,656	$ 992
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		1,074,939
Issuance of common stock upon exercise of stock options	43,310		43,310
Issuance of common stock upon vesting of restricted stock units (in shares)		663,283
Shares withheld related to net share settlement (in shares)		(122,612)
Shares withheld related to net share settlement	(37,624)		(37,624)
Stock-based compensation expense	173,791		173,791
Change in other comprehensive loss	(6,730)				(6,730)
Net income	330,294			330,294
Ending balance (in shares) at Oct. 31, 2021		153,672,418
Ending balance at Oct. 31, 2021	2,769,361	$ 2	1,145,147	1,629,950	(5,738)
Beginning balance (in shares) at Jul. 31, 2021		153,358,259
Beginning balance at Jul. 31, 2021	2,620,097	$ 2	1,098,703	1,524,081	(2,689)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		185,148
Issuance of common stock upon exercise of stock options	5,368		5,368
Issuance of common stock upon vesting of restricted stock units (in shares)		197,998
Shares withheld related to net share settlement (in shares)		(68,987)
Shares withheld related to net share settlement	(21,239)		(21,239)
Stock-based compensation expense	62,315		62,315
Change in other comprehensive loss	(3,049)				(3,049)
Net income	105,869			105,869
Ending balance (in shares) at Oct. 31, 2021		153,672,418
Ending balance at Oct. 31, 2021	2,769,361	$ 2	1,145,147	1,629,950	(5,738)
Beginning balance (in shares) at Jan. 31, 2022		154,196,597
Beginning balance at Jan. 31, 2022	$ 2,911,637	$ 2	1,196,547	1,727,046	(11,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	978,792	978,792
Issuance of common stock upon exercise of stock options	$ 30,116		30,116
Issuance of common stock upon vesting of restricted stock units (in shares)		702,297
Shares withheld related to net share settlement (in shares)		(245,662)
Shares withheld related to net share settlement	(48,152)		(48,152)
Stock-based compensation expense	259,702		259,702
Change in other comprehensive loss	(33,684)				(33,684)
Net income	299,173			299,173
Ending balance (in shares) at Oct. 31, 2022		155,632,024
Ending balance at Oct. 31, 2022	3,418,792	$ 2	1,438,213	2,026,219	(45,642)
Beginning balance (in shares) at Jul. 31, 2022		155,224,674
Beginning balance at Jul. 31, 2022	3,243,931	$ 2	1,353,502	1,917,762	(27,335)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		233,435
Issuance of common stock upon exercise of stock options	4,575		4,575
Issuance of common stock upon vesting of restricted stock units (in shares)		263,447
Shares withheld related to net share settlement (in shares)		(89,532)
Shares withheld related to net share settlement	(15,481)		(15,481)
Stock-based compensation expense	95,617		95,617
Change in other comprehensive loss	(18,307)				(18,307)
Net income	108,457			108,457
Ending balance (in shares) at Oct. 31, 2022		155,632,024
Ending balance at Oct. 31, 2022	$ 3,418,792	$ 2	$ 1,438,213	$ 2,026,219	$ (45,642)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Cash flows from operating activities
Net income	$ 108,457	$ 105,869	$ 299,173	$ 330,294
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	7,157	6,899	21,443	20,407
Reduction of operating lease right-of-use assets	3,094	2,855	9,062	8,556
(Accretion) amortization of discount on short-term investments	(1,565)	1,574	(1,016)	4,859
Stock-based compensation	93,187	62,045	256,363	172,919
Amortization of deferred costs	5,378	6,597	17,107	19,426
Deferred income taxes	(31,056)	(2,021)	(84,369)	10,174
Loss (gain) on foreign currency from mark-to-market derivative	7	(65)	1,193	368
Bad debt expense	1,089	58	1,210	195
Changes in operating assets and liabilities:
Accounts receivable	69,272	72,147	387,066	352,470
Unbilled accounts receivable	(4,307)	(16,870)	(18,819)	(20,764)
Deferred costs	(5,376)	(3,353)	(11,876)	(11,445)
Prepaid expenses and other current and long-term assets	7,326	4,407	(3,750)	3,278
Accounts payable	10,002	4,028	20,663	2,265
Accrued expenses and other current liabilities	5,465	(537)	2,654	8,646
Income taxes payable	49,323	12,010	46,705	11,993
Deferred revenue	(174,544)	(141,083)	(222,013)	(199,042)
Operating lease liabilities	(2,624)	(2,941)	(7,736)	(8,602)
Other long-term liabilities	2,375	1,340	4,013	4,412
Net cash provided by operating activities	142,660	112,959	717,073	710,409
Cash flows from investing activities
Purchases of short-term investments	(710,833)	(256,008)	(1,716,250)	(935,626)
Maturities and sales of short-term investments	310,713	248,093	757,434	657,062
Acquisitions, net of cash acquired	0	0	0	(2,133)
Long-term assets	(5,609)	(2,314)	(9,605)	(10,295)
Net cash used in investing activities	(405,729)	(10,229)	(968,421)	(290,992)
Cash flows from financing activities
Changes in lease liabilities - finance leases	0	0	0	(384)
Proceeds from exercise of common stock options	4,575	5,368	30,116	43,310
Taxes paid related to net share settlement of equity awards	(15,118)	(21,414)	(47,251)	(36,510)
Net cash (used in) provided by financing activities	(10,543)	(16,046)	(17,135)	6,416
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(1,475)	(1,469)	(4,398)	(4,414)
Net change in cash, cash equivalents, and restricted cash	(275,087)	85,215	(272,881)	421,419
Cash, cash equivalents, and restricted cash at beginning of period	1,143,431	1,067,916	1,141,225	731,712
Cash, cash equivalents, and restricted cash at end of period	868,344	1,153,131	868,344	1,153,131
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	865,159	1,149,946	865,159	1,149,946
Restricted cash included in other long-term assets	3,185	3,185	3,185	3,185
Cash, cash equivalents, and restricted cash at end of period	868,344	1,153,131	868,344	1,153,131
Supplemental disclosures of other cash flow information:
Cash paid for income taxes, net of refunds	2,936	14,167	110,708	34,668
Excess tax benefits from employee stock plans	888	10,404	5,981	45,464
Non-cash investing activities:
Changes in accounts payable and accrued expenses related to property and equipment purchases	$ (17)	$ (223)	$ (458)	$ (2,024)

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	9 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	Summary of Business and Significant Accounting Policies Description of Business Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in the consumer product and chemical industries. Our fiscal year end is January 31. Principles of Consolidation and Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2022, filed on March 30, 2022. There have been no changes to our significant accounting policies described in the annual report that have had a material impact on our condensed consolidated financial statements and related notes. The unaudited condensed consolidated balance sheet as of January 31, 2022 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly our financial position, results of operations, comprehensive income, and cash flows for the interim periods but are not necessarily indicative of the results of operations to be anticipated for the full fiscal year ending January 31, 2023 or any other period. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect the condensed consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the condensed consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to: • the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations; • the determination of the period of benefit for amortization of deferred costs; • the realizability of deferred income tax assets; • the fair value of our stock-based awards. As future events cannot be determined with precision, actual results could differ significantly from those estimates.

Short-Term Investments

Short-Term Investments	9 Months Ended
	Oct. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Short-Term Investments	Short-Term Investments At October 31, 2022, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 68,951 $ — $ (233) $ 68,718 Asset-backed securities 425,183 2 (8,584) 416,601 Commercial paper 147,822 — (1,207) 146,615 Corporate notes and bonds 1,123,950 51 (28,601) 1,095,400 Foreign government bonds 25,714 1 (691) 25,024 U.S. agency obligations 32,992 5 (837) 32,160 U.S. treasury securities 382,388 — (9,510) 372,878 Total available-for-sale securities $ 2,207,000 $ 59 $ (49,663) $ 2,157,396 At January 31, 2022, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 13,500 $ — $ (15) $ 13,485 Asset-backed securities 191,676 45 (1,432) 190,289 Commercial paper 29,432 — (2) 29,430 Corporate notes and bonds 669,489 276 (5,856) 663,909 Foreign government bonds 24,577 13 (179) 24,411 U.S. agency obligations 27,978 12 (254) 27,736 U.S. treasury securities 290,513 46 (1,755) 288,804 Total available-for-sale securities $ 1,247,165 $ 392 $ (9,493) $ 1,238,064 The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands): October 31, January 31, Due in one year or less $ 874,735 $ 457,948 Due in greater than one year 1,282,661 780,116 Total $ 2,157,396 $ 1,238,064 We have not recorded an allowance for credit losses, as we believe any such losses would be immaterial based on the high credit quality of our investments. We intend to hold our securities to maturity and it is more likely than not that we will hold these securities until recovery of the cost basis. The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of October 31, 2022 (in thousands): Less than 12 months 12 months or greater Fair Gross Fair Gross Certificates of deposits $ 63,717 $ (233) $ — $ — Asset-backed securities 335,172 (5,905) 67,697 (2,679) Commercial paper 146,615 (1,207) — — Corporate notes and bonds 809,703 (17,598) 258,113 (11,003) Foreign government bonds 11,222 (186) 11,711 (505) U.S. agency obligations 11,931 (266) 17,223 (571) U.S. treasury securities 277,077 (6,320) 95,803 (3,190) The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2022 (in thousands): Less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 5,985 $ (15) Asset-backed securities 177,056 (1,432) Commercial paper 17,190 (2) Corporate notes and bonds 571,099 (5,856) Foreign government bonds 19,594 (179) U.S. agency obligations 24,725 (254) U.S. treasury securities 247,509 (1,756)

Deferred Costs

Deferred Costs	9 Months Ended
	Oct. 31, 2022
Deferred Costs [Abstract]
Deferred Costs	Deferred CostsDeferred costs, which consist of deferred sales commissions, were $28 million and $33 million as of October 31, 2022 and January 31, 2022, respectively. Amortization expense for the deferred costs included in sales and marketing expenses in the condensed consolidated statements of comprehensive income was $5 million and $17 million for the three and nine months ended October 31, 2022, respectively, and $7 million and $19 million for the three and nine months ended October 31, 2021, respectively. There have been no impairment losses recorded in relation to the costs capitalized for any period presented.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Oct. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net consists of the following as of the dates shown (in thousands): October 31, January 31, Land $ 3,040 $ 3,040 Building 20,984 20,984 Land improvements and building improvements 22,392 22,392 Equipment and computers 2,125 3,581 Furniture and fixtures 14,674 15,040 Leasehold improvements 19,200 19,002 Construction in progress 130 730 82,545 84,769 Less accumulated depreciation (31,410) (30,274) Total property and equipment, net $ 51,135 $ 54,495

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Oct. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill was $440 million as of October 31, 2022 and January 31, 2022. The following schedule presents the details of intangible assets as of October 31, 2022 (dollar amounts in thousands): October 31, 2022 Gross carrying amount Accumulated amortization Net Remaining useful life (in years) Existing technology $ 28,580 $ (15,351) $ 13,229 3.2 Customer relationships 113,157 (47,404) 65,753 6.3 Trade name/trademarks 13,900 (8,620) 5,280 2.0 Other intangibles 21,405 (18,285) 3,120 3.2 $ 177,042 $ (89,660) $ 87,382 The following schedule presents the details of intangible assets as of January 31, 2022 (dollar amounts in thousands): January 31, 2022 Gross Accumulated Net Remaining Existing technology $ 28,580 $ (12,187) $ 16,393 3.9 Customer relationships 113,157 (38,829) 74,328 7.0 Trade name/trademarks 13,900 (6,645) 7,255 2.8 Other intangibles 21,405 (17,441) 3,964 3.8 $ 177,042 $ (75,102) $ 101,940 Amortization expense associated with intangible assets was $5 million and $15 million for the three and nine months ended October 31, 2022, respectively, and $5 million and $14 million for the three and nine months ended October 31, 2021, respectively. As of October 31, 2022, the estimated amortization expense for intangible assets was as follows (in thousands): Fiscal Year Estimated Remaining for 2023 $ 4,906 2024 19,459 2025 18,557 2026 14,147 2027 8,922 Thereafter 21,391 Total $ 87,382

Accrued Expenses

Accrued Expenses	9 Months Ended
	Oct. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consisted of the following as of the dates shown (in thousands): October 31, January 31, Accrued commissions $ 8,006 $ 8,556 Accrued bonus 3,321 4,677 Accrued vacation (1) 6,068 5,546 Payroll tax payable 14,847 9,487 Accrued other compensation and benefits 8,023 5,568 Total accrued compensation and benefits $ 40,265 $ 33,834 Accrued fees payable to Salesforce, Inc. 6,723 $ 6,521 Taxes payable 5,596 9,743 Accrued third-party professional services subcontractors' fees 2,409 1,961 Other accrued expenses 18,132 17,884 Total accrued expenses and other current liabilities $ 32,860 $ 36,109 (1) Represents accrued vacation primarily for international employees. Vacation does not accrue for most U.S. employees.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of accounts receivable and other current assets, accounts payable, and accrued liabilities approximate their fair value due to their short-term nature. Financial assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability. The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of October 31, 2022 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 117,017 $ — $ 117,017 Commercial paper — 43,866 43,866 Corporate notes and bonds — 6,673 6,673 Short-term investments: Certificates of deposit — 68,718 68,718 Asset-backed securities — 416,601 416,601 Commercial paper — 146,615 146,615 Corporate notes and bonds — 1,095,400 1,095,400 Foreign government bonds — 25,024 25,024 U.S. agency obligations — 32,160 32,160 U.S. treasury securities — 372,878 372,878 Foreign currency derivative contracts — 29 29 Total financial assets $ 117,017 $ 2,207,964 $ 2,324,981 The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2022 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 428,411 $ — $ 428,411 Corporate notes and bonds — 5,853 5,853 Asset-backed securities — 2,568 2,568 Short-term investments: Certificates of deposit — 13,485 13,485 Asset-backed securities — 190,289 190,289 Commercial paper — 29,430 29,430 Corporate notes and bonds — 663,909 663,909 Foreign government bonds — 24,411 24,411 U.S. agency obligations — 27,736 27,736 U.S. treasury securities — 288,804 288,804 Foreign currency derivative contracts — 1,222 1,222 Total financial assets $ 428,411 $ 1,247,707 $ 1,676,118 We determine the fair value of our security holdings based on pricing from our service providers and market prices from industry-standard independent data providers. The valuation techniques used to measure the fair value of financial instruments having Level 2 inputs were derived from non-binding consensus prices that are corroborated by observable market data or quoted market prices for similar instruments. Such market prices may be quoted prices in active markets for identical assets (Level 1 inputs) or pricing determined using inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs). Balance Sheet Hedges We enter into foreign currency forward contracts in order to hedge our foreign currency exposure. These forward contracts are not designated as hedging instruments under applicable accounting guidance, and therefore, we account for them at fair value with changes in the fair value recorded as a component of other income, net in our condensed consolidated statements of comprehensive income. Cash flows from such forward contracts are classified as operating activities. We recognized realized foreign currency gains of $2 million and $10 million for the three and nine months ended October 31, 2022, respectively. Recognized realized foreign currency losses were not material for the three and nine months ended October 31, 2021. The fair value of our outstanding derivative instruments is summarized below (in thousands): October 31, January 31, Notional amount of foreign currency derivative contracts $ 50,039 $ 87,097 Fair value of foreign currency derivative contracts 50,685 85,876 Details on outstanding balance sheet hedges are presented below as of the date shown below (in thousands): Derivatives not designated as hedging instruments Balance sheet location October 31, January 31, Derivative Assets Foreign currency derivative contracts Prepaid expenses and other current assets $ 29 $ 1,222 Derivative Liabilities Foreign currency derivative contracts Accrued expenses $ (675) $ —

Income Taxes

Income Taxes	9 Months Ended
	Oct. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended October 31, 2022 and 2021, our effective tax rates were 19.0% and 20.7%, respectively. During the three months ended October 31, 2022, as compared to the prior year period, our effective tax rate decreased primarily due an increase in the foreign derived intangible income deduction and a reduced valuation allowance impact within certain jurisdictions. These increases were partially offset by a reduction in excess tax benefits related to equity compensation. We recognized excess tax benefits in our provision for income taxes of $1 million and $10 million for the three months ended October 31, 2022 and 2021, respectively. For the nine months ended October 31, 2022 and 2021, our effective tax rates were 20.0% and 15.9%, respectively. During the nine months ended October 31, 2022 as compared to the prior year period, our effective tax rate increased primarily due to a reduction in excess tax benefits related to equity compensation partially offset by an increase in the foreign derived intangible income deduction. We recognized such excess tax benefits in our provision for income taxes of $10 million and $45 million for the nine months ended October 31, 2022 and 2021, respectively.

Deferred Revenue, Performance O

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable	9 Months Ended
	Oct. 31, 2022
Contract with Customer, Liability [Abstract]
Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable	Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable Of the beginning deferred revenue balance for the respective periods, we recognized $358 million and $638 million of subscription services revenue during the three and nine months ended October 31, 2022, and $296 million and $535 million for the three and nine months ended October 31, 2021, respectively. Professional services revenue recognized in the same periods from deferred revenue balances at the beginning of the respective periods was immaterial. Transaction Price Allocated to the Remaining Performance Obligations Transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. We applied the practical expedient in accordance with ASU 2014-09, “ Revenue from Contracts with Customers ” (Topic 606) to exclude the amounts related to professional services contracts as these contracts generally have a remaining duration of one year or less. As of October 31, 2022, approximately $1,189 million of revenue is expected to be recognized from remaining performance obligations for subscription services contracts. We expect to recognize revenue on approximately 73% of these remaining performance obligations over the next 12 months, with the balance recognized thereafter. Unbilled Accounts Receivable Unbilled accounts receivable consists of (i) a receivable primarily for the revenue recognized for professional services performed but not yet billed, which were $34 million and $28 million as of October 31, 2022 and January 31, 2022, respectively, and (ii) a contract asset primarily for revenue recognized from non-cancelable, multi-year orders in which fees increase annually but for which we are not contractually able to invoice until a future period, which were $48 million and $36 million as of October 31, 2022 and January 31, 2022, respectively.

Leases

Leases	9 Months Ended
	Oct. 31, 2022
Leases [Abstract]
Leases	Leases We have operating leases for our corporate offices. Our leases have various expiration dates through 2034, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for each of the three and nine months ended October 31, 2022 and 2021 was immaterial. For the three months ended October 31, 2022 and 2021, our operating lease expense was $4 million and $3 million, respectively. For the nine months ended October 31, 2022 and 2021, our operating lease expense was $12 million and $10 million, respectively. Supplemental cash flow information related to leases was as follows (in thousands): Nine months ended October 31, 2022 2021 Cash paid for operating lease liabilities $ 11,320 $ 10,288 Operating lease right-of-use assets obtained in exchange for new operating lease liabilities 13,937 2,135 Supplemental balance sheet information related to leases was as follows: October 31, 2022 January 31, 2022 Weighted Average Remaining Lease Term 6.8 years 6.0 years Weighted Average Discount Rate 4.1 % 3.7 % As of October 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal Year Remaining for 2023 $ 3,299 2024 9,405 2025 11,417 2026 9,499 2027 8,496 Thereafter 31,474 Total lease payments 73,590 Less imputed interest (11,700) Total $ 61,890
Leases	Leases We have operating leases for our corporate offices. Our leases have various expiration dates through 2034, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for each of the three and nine months ended October 31, 2022 and 2021 was immaterial. For the three months ended October 31, 2022 and 2021, our operating lease expense was $4 million and $3 million, respectively. For the nine months ended October 31, 2022 and 2021, our operating lease expense was $12 million and $10 million, respectively. Supplemental cash flow information related to leases was as follows (in thousands): Nine months ended October 31, 2022 2021 Cash paid for operating lease liabilities $ 11,320 $ 10,288 Operating lease right-of-use assets obtained in exchange for new operating lease liabilities 13,937 2,135 Supplemental balance sheet information related to leases was as follows: October 31, 2022 January 31, 2022 Weighted Average Remaining Lease Term 6.8 years 6.0 years Weighted Average Discount Rate 4.1 % 3.7 % As of October 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal Year Remaining for 2023 $ 3,299 2024 9,405 2025 11,417 2026 9,499 2027 8,496 Thereafter 31,474 Total lease payments 73,590 Less imputed interest (11,700) Total $ 61,890

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Oct. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stockholders' Equity	Stockholders’ Equity Stock Option Activity A summary of stock option activity for the nine months ended October 31, 2022 is as follows: Number of shares Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate Options outstanding at January 31, 2022 12,090,522 $ 77.89 4.6 $ 1,964 Options granted 3,178,165 206.35 Options exercised (978,792) 30.59 Options forfeited/cancelled (362,182) 208.90 Options outstanding at October 31, 2022 13,927,713 $ 107.17 5.2 $ 1,084 Options vested and exercisable at October 31, 2022 7,527,009 $ 50.78 2.8 $ 913 Options vested and exercisable at October 31, 2022 and expected to vest thereafter 13,927,713 $ 107.17 5.2 $ 1,084 The options granted during the nine months ended October 31, 2022 were predominantly made in connection with our annual performance review cycle. The weighted average grant-date fair value of options granted was $85.55 and $88.49 per option for the three and nine months ended October 31, 2022, respectively. As of October 31, 2022, there was $380 million in unrecognized compensation cost related to unvested stock options granted under the 2012 Equity Incentive Plan and 2013 Equity Incentive Plan. This cost is expected to be recognized over a weighted average period of 2.7 years. As of October 31, 2022, we had authorized and unissued shares of common stock sufficient to satisfy exercises of stock options. The total intrinsic value of options exercised was approximately $37 million and $165 million for the three and nine months ended October 31, 2022, respectively. Stock Option Valuation Assumptions The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented: Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Volatility 39% - 40% 37% 37% - 40% 37% - 39% Expected term (in years) 6.25 6.25 6 - 7 6.25 Risk-free interest rate 2.90% - 4.20% 0.90% - 1.30% 1.90 % - 4.20 % 0.68 % - 1.30 % Dividend yield —% —% —% —% Restricted Stock Units A summary of restricted stock unit (RSU) activity for the nine months ended October 31, 2022 is as follows: Unreleased restricted stock units Weighted average grant date fair value Balance at January 31, 2022 619,388 $ 175.23 RSUs granted 1,495,425 205.95 RSUs vested (702,297) 197.62 RSUs forfeited/cancelled (84,017) 199.28 Balance at October 31, 2022 1,328,499 196.43

Net Income per Share

Net Income per Share	9 Months Ended
	Oct. 31, 2022
Earnings Per Share [Abstract]
Net Income per Share	Net Income per Share Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method. The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares. The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data): Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Class A Class B Class A Class B Class A Class B Class A Class B Basic Numerator Net income, basic $ 98,151 $ 10,306 $ 95,691 $ 10,178 $ 270,666 $ 28,507 $ 298,379 $ 31,915 Denominator Weighted average shares used in computing net income per share, basic 140,626 14,766 138,755 14,759 140,193 14,765 138,234 14,786 Net income per share, basic $ 0.70 $ 0.70 $ 0.69 $ 0.69 $ 1.93 $ 1.93 $ 2.16 $ 2.16 Diluted Numerator Net income, basic $ 98,151 $ 10,306 $ 95,691 $ 10,178 $ 270,666 $ 28,507 $ 298,379 $ 31,915 Reallocation as a result of conversion of Class B to Class A common stock: Net income, basic 10,306 — 10,178 — 28,507 — 31,915 — Reallocation of net income to Class B common stock — 4,175 — 5,588 — 12,067 — 17,690 Net income, diluted $ 108,457 $ 14,481 $ 105,869 $ 15,766 $ 299,173 $ 40,574 $ 330,294 $ 49,605 Denominator Number of shares used for basic net income per share computation 140,626 14,766 138,755 14,759 140,193 14,765 138,234 14,786 Conversion of Class B to Class A common stock 14,766 — 14,759 — 14,765 — 14,786 — Effect of potentially dilutive common shares 6,903 6,903 9,520 9,520 7,231 7,231 9,643 9,643 Weighted average shares used in computing net income per share, diluted 162,295 21,669 163,034 24,279 162,189 21,996 162,663 24,429 Net income per share, diluted $ 0.67 $ 0.67 $ 0.65 $ 0.65 $ 1.84 $ 1.84 $ 2.03 $ 2.03 Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows: Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive 5,022,968 1,105,478 4,363,631 869,044

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation IQVIA Litigation Matters Veeva OpenData and Veeva Network Action. On January 10, 2017, IQVIA Inc. (formerly Quintiles IMS Incorporated) and IMS Software Services, Ltd. (collectively, “IQVIA”) filed a complaint against us in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:17-cv-00177)). In the complaint, IQVIA alleges that we used unauthorized access to proprietary IQVIA data to improve our software and data products and that our software is designed to steal IQVIA trade secrets. IQVIA further alleges that we have intentionally gained unauthorized access to IQVIA proprietary information to gain an unfair advantage in marketing our products and that we have made false statements concerning IQVIA’s conduct and our data security capabilities. IQVIA asserts claims under both federal and state misappropriation of trade secret laws, federal false advertising law, and common law claims for unjust enrichment, tortious interference, and unfair trade practices. The complaint seeks declaratory and injunctive relief and unspecified monetary damages. On March 13, 2017, we filed our answer denying IQVIA's claims and filed counterclaims. Our counterclaims allege that IQVIA, as the dominant provider of data for life sciences companies, has abused monopoly power to exclude Veeva OpenData and Veeva Network from their respective markets. The counterclaims allege that IQVIA has engaged in various tactics to prevent customers from using our applications and has deliberately raised costs and increased the difficulty of attempting to switch from IQVIA data to our data products. As amended, our counterclaims assert federal and state antitrust claims, as well as claims under California’s Unfair Practices Act and common law claims for intentional interference with contractual relations, intentional interference with prospective economic advantage, and negligent misrepresentation. The counterclaims seek injunctive relief, monetary damages exceeding $200 million, and attorneys’ fees. On October 3, 2018, the court denied IQVIA’s motion to dismiss our antitrust claims. On February 18, 2020, IQVIA filed a motion for sanctions against Veeva, seeking default judgment and dismissal and, in the alternative, an adverse inference at trial related to discovery disputes. On May 7, 2021, the special master appointed to oversee litigation discovery ruled against IQVIA’s request for default judgment and dismissal and ruled in IQVIA’s favor with respect to certain other matters, including recommending to the trial judge that a permissive adverse inference instruction be issued to the jury with respect to certain documents that were not preserved by Veeva. Should the trial judge accept the recommendation, the jury would be permitted, but not required, to infer that certain evidence not preserved by Veeva would have been unfavorable to Veeva, if the jury first concludes that Veeva controlled the evidence, that the evidence was relevant, and that Veeva should have preserved the evidence. The jury is also likely to be instructed that it may also consider whether the non-preserved evidence was duplicative of other evidence produced by Veeva and whether Veeva’s conduct was reasonable in light of all circumstances. Veeva was also ordered to pay IQVIA’s fees and expenses incurred in connection with portions of its sanctions motion. On June 4, 2021, we appealed the special master’s ruling and IQVIA’s fee award to the federal district court judge. Fact discovery is largely complete and we expect to complete expert discovery in May 2023. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, and we are unable to make a meaningful estimate of the amount or range of gain or loss, if any, that could result from the OpenData and Network Action, we believe that IQVIA’s claims lack merit and that our counterclaims warrant injunctive relief and monetary damages for Veeva. Veeva Nitro Action. On July 17, 2019, IQVIA filed a lawsuit in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:19-cv-15517)) (IQVIA Declaratory Action) seeking a declaratory judgment that IQVIA is not liable to Veeva for disallowing use of IQVIA’s data products in Veeva Nitro or any later-introduced Veeva software products. The IQVIA Declaratory Action does not seek any monetary relief. On July 18, 2019, we filed a lawsuit against IQVIA in the U.S. District Court for the Northern District of California (Veeva Systems Inc. v. IQVIA Inc. (No. 3:19-cv-04137)) (Veeva Nitro Action), alleging that IQVIA engaged in anticompetitive conduct as to Veeva Nitro. Our complaint asserts federal and state antitrust claims, as well as claims under California’s Unfair Competition Law and common law claims for intentional interference with contractual relations and intentional interference with prospective economic advantage. The complaint seeks injunctive relief and monetary damages. IQVIA filed its answer and affirmative defenses on September 5, 2019. On September 26, 2019, the Northern District of California transferred the Veeva Nitro Action to the District of New Jersey (Veeva Systems Inc. v. IQVIA Inc. (No. 2:19-cv-18558)). On March 24, 2020, we amended our complaint in the Veeva Nitro Action to include allegations of IQVIA’s anticompetitive conduct as to additional Veeva software applications, such as Veeva Andi, Veeva Align, and Veeva Vault MedComms; additional examples of IQVIA’s monopolistic behavior against Veeva Nitro; IQVIA’s unlawful access of Veeva’s proprietary software products; and a request for declaratory relief. IQVIA answered the amended complaint on May 22, 2020. On August 21, 2020, the District of New Jersey consolidated the Veeva Nitro Action and IQVIA Declaratory Action. Fact discovery is largely complete and we expect to complete expert discovery in May 2023. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, we believe that our claims warrant injunctive and declaratory relief and monetary damages for Veeva and against IQVIA. Fee Arrangements Related to the IQVIA Litigation Matters. We have entered into partial contingency fee arrangements with certain law firms representing us in the IQVIA litigations. Pursuant to those arrangements, such law firms are entitled to an agreed portion of any damages we recover from IQVIA or may be entitled to payment of success fees from us based on the achievement of certain outcomes. While it is reasonably possible that we may incur such success fees, we are unable to make an estimate of any such liability and have not accrued any liability related to success fees at this time. Medidata Litigation Matter On January 26, 2017, Medidata Solutions, Inc. filed a complaint in the U.S. District Court for the Southern District of New York ( Medidata Solutions, Inc. v. Veeva Systems Inc. et al. (No. 1:17-cv-00589)) against us and five individual Veeva employees who previously worked for Medidata (“Individual Employees”). The complaint alleged that we induced and conspired with the Individual Employees to breach their employment agreements, including non-compete and confidentiality provisions, and to misappropriate Medidata’s confidential and trade secret information. The complaint sought declaratory and injunctive relief, unspecified monetary damages, and attorneys’ fees. Medidata amended its complaint twice, asserting the same claims with additional factual allegations, and voluntarily dismissed the Individual Defendants without prejudice. The trial began on July 11, 2022. On July 15, 2022, after four days of jury trial, the court granted Veeva’s motion for judgment as a matter of law, thereby resolving the case in favor of Veeva. Medidata moved for reconsideration of the decision on July 29, 2022, which was denied by the court on August 18, 2022. Medidata filed a notice of its intent to appeal in the Second Circuit Court of Appeals on September 16, 2022, which remains pending, but has not yet filed its appeal. Other Litigation Matters From time to time, we may be involved in other legal proceedings and subject to claims incident to the ordinary course of business. Although the results of such legal proceedings and claims cannot be predicted with certainty, we believe we are not currently a party to any other legal proceedings, the outcome of which, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows, or financial position. Regardless of the outcome, such proceedings can have an adverse impact on us because of defense and settlement costs, diversion of resources, and other factors, and there can be no assurances that favorable outcomes will be obtained.

Revenues by Product

Revenues by Product	9 Months Ended
	Oct. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenues by Product	Revenues by Product We group our revenues into two product areas: Commercial Solutions and R&D Solutions. Commercial Solutions revenues consist of revenues from our Veeva Commercial Cloud, Veeva Data Cloud, and Veeva Claims solutions. R&D Solutions consist of revenues from our Veeva Development Cloud, Veeva RegulatoryOne, and Veeva QualityOne solutions. Total revenues consist of the following (in thousands): Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Subscription services Commercial Solutions $ 239,276 $ 223,183 $ 703,356 $ 649,156 R&D Solutions 202,293 157,555 569,494 439,137 Total subscription services $ 441,569 $ 380,738 $ 1,272,850 $ 1,088,293 Professional services Commercial Solutions $ 45,283 $ 41,675 $ 133,027 $ 124,241 R&D Solutions 65,499 53,698 185,794 152,744 Total professional services $ 110,782 $ 95,373 $ 318,821 $ 276,985 Total revenues $ 552,351 $ 476,111 $ 1,591,671 $ 1,365,278

Information about Geographic Ar

Information about Geographic Areas	9 Months Ended
	Oct. 31, 2022
Segment Reporting [Abstract]
Information about Geographic Areas	Information about Geographic Areas We track and allocate revenues by principal geographic area rather than by individual country, which makes it impractical to disclose revenues for the United States or other specific foreign countries. We measure subscription services revenue primarily by the estimated location of the end users in each geographic area for our Commercial Solutions and primarily by the estimated location of usage in each geographic area for our R&D Solutions. We measure professional services revenue primarily by the location of the resources performing the professional services. Total revenues by geographic area were as follows for the periods shown below (in thousands): Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Revenues by geography North America $ 321,860 $ 277,165 $ 925,589 $ 782,590 Europe 152,951 128,032 441,719 376,885 Asia Pacific 62,621 57,837 181,286 167,319 Middle East, Africa, and Latin America 14,919 13,077 43,077 38,484 Total revenues $ 552,351 $ 476,111 $ 1,591,671 $ 1,365,278 Long-lived assets by geographic area are as follows as of the periods shown below (in thousands): October 31, January 31, Long-lived assets by geography North America $ 43,069 $ 45,625 Europe 5,552 6,135 Asia Pacific 902 1,335 Middle East, Africa, and Latin America 1,612 1,400 Total long-lived assets $ 51,135 $ 54,495

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 31, 2022
Accounting Policies [Abstract]
Description of Business	Description of Business Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in the consumer product and chemical industries. Our fiscal year end is January 31.
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2022, filed on March 30, 2022. There have been no changes to our significant accounting policies described in the annual report that have had a material impact on our condensed consolidated financial statements and related notes. The unaudited condensed consolidated balance sheet as of January 31, 2022 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly our financial position, results of operations, comprehensive income, and cash flows for the interim periods but are not necessarily indicative of the results of operations to be anticipated for the full fiscal year ending January 31, 2023 or any other period.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect the condensed consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the condensed consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to: • the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations; • the determination of the period of benefit for amortization of deferred costs; • the realizability of deferred income tax assets; • the fair value of our stock-based awards. As future events cannot be determined with precision, actual results could differ significantly from those estimates.
Fair Value Measurements	Financial assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability.
Net Income per Share Attributable to Common Stockholders	Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method. The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares.

Short-Term Investments (Tables)

Short-Term Investments (Tables)	9 Months Ended
	Oct. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Short-Term Investments	At October 31, 2022, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 68,951 $ — $ (233) $ 68,718 Asset-backed securities 425,183 2 (8,584) 416,601 Commercial paper 147,822 — (1,207) 146,615 Corporate notes and bonds 1,123,950 51 (28,601) 1,095,400 Foreign government bonds 25,714 1 (691) 25,024 U.S. agency obligations 32,992 5 (837) 32,160 U.S. treasury securities 382,388 — (9,510) 372,878 Total available-for-sale securities $ 2,207,000 $ 59 $ (49,663) $ 2,157,396 At January 31, 2022, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 13,500 $ — $ (15) $ 13,485 Asset-backed securities 191,676 45 (1,432) 190,289 Commercial paper 29,432 — (2) 29,430 Corporate notes and bonds 669,489 276 (5,856) 663,909 Foreign government bonds 24,577 13 (179) 24,411 U.S. agency obligations 27,978 12 (254) 27,736 U.S. treasury securities 290,513 46 (1,755) 288,804 Total available-for-sale securities $ 1,247,165 $ 392 $ (9,493) $ 1,238,064
Summary of Estimated Fair Value of Short-Term Investments, Designated as Available-for-Sale and Classified by Contractual Maturity	The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands): October 31, January 31, Due in one year or less $ 874,735 $ 457,948 Due in greater than one year 1,282,661 780,116 Total $ 2,157,396 $ 1,238,064
Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category	The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of October 31, 2022 (in thousands): Less than 12 months 12 months or greater Fair Gross Fair Gross Certificates of deposits $ 63,717 $ (233) $ — $ — Asset-backed securities 335,172 (5,905) 67,697 (2,679) Commercial paper 146,615 (1,207) — — Corporate notes and bonds 809,703 (17,598) 258,113 (11,003) Foreign government bonds 11,222 (186) 11,711 (505) U.S. agency obligations 11,931 (266) 17,223 (571) U.S. treasury securities 277,077 (6,320) 95,803 (3,190) The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2022 (in thousands): Less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 5,985 $ (15) Asset-backed securities 177,056 (1,432) Commercial paper 17,190 (2) Corporate notes and bonds 571,099 (5,856) Foreign government bonds 19,594 (179) U.S. agency obligations 24,725 (254) U.S. treasury securities 247,509 (1,756)

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Oct. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consists of the following as of the dates shown (in thousands): October 31, January 31, Land $ 3,040 $ 3,040 Building 20,984 20,984 Land improvements and building improvements 22,392 22,392 Equipment and computers 2,125 3,581 Furniture and fixtures 14,674 15,040 Leasehold improvements 19,200 19,002 Construction in progress 130 730 82,545 84,769 Less accumulated depreciation (31,410) (30,274) Total property and equipment, net $ 51,135 $ 54,495

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Oct. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Details of Intangible Assets	The following schedule presents the details of intangible assets as of October 31, 2022 (dollar amounts in thousands): October 31, 2022 Gross carrying amount Accumulated amortization Net Remaining useful life (in years) Existing technology $ 28,580 $ (15,351) $ 13,229 3.2 Customer relationships 113,157 (47,404) 65,753 6.3 Trade name/trademarks 13,900 (8,620) 5,280 2.0 Other intangibles 21,405 (18,285) 3,120 3.2 $ 177,042 $ (89,660) $ 87,382 The following schedule presents the details of intangible assets as of January 31, 2022 (dollar amounts in thousands): January 31, 2022 Gross Accumulated Net Remaining Existing technology $ 28,580 $ (12,187) $ 16,393 3.9 Customer relationships 113,157 (38,829) 74,328 7.0 Trade name/trademarks 13,900 (6,645) 7,255 2.8 Other intangibles 21,405 (17,441) 3,964 3.8 $ 177,042 $ (75,102) $ 101,940
Estimated Amortization Expense	As of October 31, 2022, the estimated amortization expense for intangible assets was as follows (in thousands): Fiscal Year Estimated Remaining for 2023 $ 4,906 2024 19,459 2025 18,557 2026 14,147 2027 8,922 Thereafter 21,391 Total $ 87,382

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Oct. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following as of the dates shown (in thousands): October 31, January 31, Accrued commissions $ 8,006 $ 8,556 Accrued bonus 3,321 4,677 Accrued vacation (1) 6,068 5,546 Payroll tax payable 14,847 9,487 Accrued other compensation and benefits 8,023 5,568 Total accrued compensation and benefits $ 40,265 $ 33,834 Accrued fees payable to Salesforce, Inc. 6,723 $ 6,521 Taxes payable 5,596 9,743 Accrued third-party professional services subcontractors' fees 2,409 1,961 Other accrued expenses 18,132 17,884 Total accrued expenses and other current liabilities $ 32,860 $ 36,109 (1) Represents accrued vacation primarily for international employees. Vacation does not accrue for most U.S. employees.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of October 31, 2022 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 117,017 $ — $ 117,017 Commercial paper — 43,866 43,866 Corporate notes and bonds — 6,673 6,673 Short-term investments: Certificates of deposit — 68,718 68,718 Asset-backed securities — 416,601 416,601 Commercial paper — 146,615 146,615 Corporate notes and bonds — 1,095,400 1,095,400 Foreign government bonds — 25,024 25,024 U.S. agency obligations — 32,160 32,160 U.S. treasury securities — 372,878 372,878 Foreign currency derivative contracts — 29 29 Total financial assets $ 117,017 $ 2,207,964 $ 2,324,981 The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2022 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 428,411 $ — $ 428,411 Corporate notes and bonds — 5,853 5,853 Asset-backed securities — 2,568 2,568 Short-term investments: Certificates of deposit — 13,485 13,485 Asset-backed securities — 190,289 190,289 Commercial paper — 29,430 29,430 Corporate notes and bonds — 663,909 663,909 Foreign government bonds — 24,411 24,411 U.S. agency obligations — 27,736 27,736 U.S. treasury securities — 288,804 288,804 Foreign currency derivative contracts — 1,222 1,222 Total financial assets $ 428,411 $ 1,247,707 $ 1,676,118
Summary Fair Value of Outstanding Derivative Instruments	The fair value of our outstanding derivative instruments is summarized below (in thousands): October 31, January 31, Notional amount of foreign currency derivative contracts $ 50,039 $ 87,097 Fair value of foreign currency derivative contracts 50,685 85,876
Summary of Outstanding Balance Sheet Hedges	Details on outstanding balance sheet hedges are presented below as of the date shown below (in thousands): Derivatives not designated as hedging instruments Balance sheet location October 31, January 31, Derivative Assets Foreign currency derivative contracts Prepaid expenses and other current assets $ 29 $ 1,222 Derivative Liabilities Foreign currency derivative contracts Accrued expenses $ (675) $ —

Leases (Tables)

Leases (Tables)	9 Months Ended
	Oct. 31, 2022
Leases [Abstract]
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows (in thousands): Nine months ended October 31, 2022 2021 Cash paid for operating lease liabilities $ 11,320 $ 10,288 Operating lease right-of-use assets obtained in exchange for new operating lease liabilities 13,937 2,135
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was as follows: October 31, 2022 January 31, 2022 Weighted Average Remaining Lease Term 6.8 years 6.0 years Weighted Average Discount Rate 4.1 % 3.7 %
Maturity of Operating Lease Liabilities	As of October 31, 2022, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal Year Remaining for 2023 $ 3,299 2024 9,405 2025 11,417 2026 9,499 2027 8,496 Thereafter 31,474 Total lease payments 73,590 Less imputed interest (11,700) Total $ 61,890

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Oct. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the nine months ended October 31, 2022 is as follows: Number of shares Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate Options outstanding at January 31, 2022 12,090,522 $ 77.89 4.6 $ 1,964 Options granted 3,178,165 206.35 Options exercised (978,792) 30.59 Options forfeited/cancelled (362,182) 208.90 Options outstanding at October 31, 2022 13,927,713 $ 107.17 5.2 $ 1,084 Options vested and exercisable at October 31, 2022 7,527,009 $ 50.78 2.8 $ 913 Options vested and exercisable at October 31, 2022 and expected to vest thereafter 13,927,713 $ 107.17 5.2 $ 1,084
Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted	The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented: Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Volatility 39% - 40% 37% 37% - 40% 37% - 39% Expected term (in years) 6.25 6.25 6 - 7 6.25 Risk-free interest rate 2.90% - 4.20% 0.90% - 1.30% 1.90 % - 4.20 % 0.68 % - 1.30 % Dividend yield —% —% —% —%
Summary of Restricted Stock Unit (RSU) Activity	A summary of restricted stock unit (RSU) activity for the nine months ended October 31, 2022 is as follows: Unreleased restricted stock units Weighted average grant date fair value Balance at January 31, 2022 619,388 $ 175.23 RSUs granted 1,495,425 205.95 RSUs vested (702,297) 197.62 RSUs forfeited/cancelled (84,017) 199.28 Balance at October 31, 2022 1,328,499 196.43

Net Income per Share (Tables)

Net Income per Share (Tables)	9 Months Ended
	Oct. 31, 2022
Earnings Per Share [Abstract]
Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock	The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data): Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Class A Class B Class A Class B Class A Class B Class A Class B Basic Numerator Net income, basic $ 98,151 $ 10,306 $ 95,691 $ 10,178 $ 270,666 $ 28,507 $ 298,379 $ 31,915 Denominator Weighted average shares used in computing net income per share, basic 140,626 14,766 138,755 14,759 140,193 14,765 138,234 14,786 Net income per share, basic $ 0.70 $ 0.70 $ 0.69 $ 0.69 $ 1.93 $ 1.93 $ 2.16 $ 2.16 Diluted Numerator Net income, basic $ 98,151 $ 10,306 $ 95,691 $ 10,178 $ 270,666 $ 28,507 $ 298,379 $ 31,915 Reallocation as a result of conversion of Class B to Class A common stock: Net income, basic 10,306 — 10,178 — 28,507 — 31,915 — Reallocation of net income to Class B common stock — 4,175 — 5,588 — 12,067 — 17,690 Net income, diluted $ 108,457 $ 14,481 $ 105,869 $ 15,766 $ 299,173 $ 40,574 $ 330,294 $ 49,605 Denominator Number of shares used for basic net income per share computation 140,626 14,766 138,755 14,759 140,193 14,765 138,234 14,786 Conversion of Class B to Class A common stock 14,766 — 14,759 — 14,765 — 14,786 — Effect of potentially dilutive common shares 6,903 6,903 9,520 9,520 7,231 7,231 9,643 9,643 Weighted average shares used in computing net income per share, diluted 162,295 21,669 163,034 24,279 162,189 21,996 162,663 24,429 Net income per share, diluted $ 0.67 $ 0.67 $ 0.65 $ 0.65 $ 1.84 $ 1.84 $ 2.03 $ 2.03
Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive	Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows: Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive 5,022,968 1,105,478 4,363,631 869,044

Revenues by Product (Tables)

Revenues by Product (Tables)	9 Months Ended
	Oct. 31, 2022
Revenue from Contract with Customer [Abstract]
Summary of Total Revenues	Total revenues consist of the following (in thousands): Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Subscription services Commercial Solutions $ 239,276 $ 223,183 $ 703,356 $ 649,156 R&D Solutions 202,293 157,555 569,494 439,137 Total subscription services $ 441,569 $ 380,738 $ 1,272,850 $ 1,088,293 Professional services Commercial Solutions $ 45,283 $ 41,675 $ 133,027 $ 124,241 R&D Solutions 65,499 53,698 185,794 152,744 Total professional services $ 110,782 $ 95,373 $ 318,821 $ 276,985 Total revenues $ 552,351 $ 476,111 $ 1,591,671 $ 1,365,278

Information about Geographic _2

Information about Geographic Areas (Tables)	9 Months Ended
	Oct. 31, 2022
Segment Reporting [Abstract]
Revenues by Geographic Area	Total revenues by geographic area were as follows for the periods shown below (in thousands): Three months ended October 31, Nine months ended October 31, 2022 2021 2022 2021 Revenues by geography North America $ 321,860 $ 277,165 $ 925,589 $ 782,590 Europe 152,951 128,032 441,719 376,885 Asia Pacific 62,621 57,837 181,286 167,319 Middle East, Africa, and Latin America 14,919 13,077 43,077 38,484 Total revenues $ 552,351 $ 476,111 $ 1,591,671 $ 1,365,278
Long-Lived Assets by Geographic Area	Long-lived assets by geographic area are as follows as of the periods shown below (in thousands): October 31, January 31, Long-lived assets by geography North America $ 43,069 $ 45,625 Europe 5,552 6,135 Asia Pacific 902 1,335 Middle East, Africa, and Latin America 1,612 1,400 Total long-lived assets $ 51,135 $ 54,495

Short-Term Investments - Schedu

Short-Term Investments - Schedule of Short-Term Investments (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 2,207,000	$ 1,247,165
Gross unrealized gains	59	392
Gross unrealized losses	(49,663)	(9,493)
Estimated fair value	2,157,396	1,238,064
Certificates of deposits
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	68,951	13,500
Gross unrealized gains	0	0
Gross unrealized losses	(233)	(15)
Estimated fair value	68,718	13,485
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	425,183	191,676
Gross unrealized gains	2	45
Gross unrealized losses	(8,584)	(1,432)
Estimated fair value	416,601	190,289
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	147,822	29,432
Gross unrealized gains	0	0
Gross unrealized losses	(1,207)	(2)
Estimated fair value	146,615	29,430
Corporate notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,123,950	669,489
Gross unrealized gains	51	276
Gross unrealized losses	(28,601)	(5,856)
Estimated fair value	1,095,400	663,909
Foreign government bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	25,714	24,577
Gross unrealized gains	1	13
Gross unrealized losses	(691)	(179)
Estimated fair value	25,024	24,411
U.S. agency obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	32,992	27,978
Gross unrealized gains	5	12
Gross unrealized losses	(837)	(254)
Estimated fair value	32,160	27,736
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	382,388	290,513
Gross unrealized gains	0	46
Gross unrealized losses	(9,510)	(1,755)
Estimated fair value	$ 372,878	$ 288,804

Short-Term Investments - Summar

Short-Term Investments - Summary of Estimated Fair Value of Short-Term Investments, Designated as Available-for-Sale and Classified by Contractual Maturity (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 874,735	$ 457,948
Due in greater than one year	1,282,661	780,116
Total	$ 2,157,396	$ 1,238,064

Short-Term Investments - Sche_2

Short-Term Investments - Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Certificates of deposits
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	$ 63,717	$ 5,985
Less than 12 months, Gross unrealized losses	(233)	(15)
12 months or greater, Fair value	0
12 months or greater, Gross unrealized losses	0
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	335,172	177,056
Less than 12 months, Gross unrealized losses	(5,905)	(1,432)
12 months or greater, Fair value	67,697
12 months or greater, Gross unrealized losses	(2,679)
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	146,615	17,190
Less than 12 months, Gross unrealized losses	(1,207)	(2)
12 months or greater, Fair value	0
12 months or greater, Gross unrealized losses	0
Corporate notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	809,703	571,099
Less than 12 months, Gross unrealized losses	(17,598)	(5,856)
12 months or greater, Fair value	258,113
12 months or greater, Gross unrealized losses	(11,003)
Foreign government bonds
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	11,222	19,594
Less than 12 months, Gross unrealized losses	(186)	(179)
12 months or greater, Fair value	11,711
12 months or greater, Gross unrealized losses	(505)
U.S. agency obligations
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	11,931	24,725
Less than 12 months, Gross unrealized losses	(266)	(254)
12 months or greater, Fair value	17,223
12 months or greater, Gross unrealized losses	(571)
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	277,077	247,509
Less than 12 months, Gross unrealized losses	(6,320)	$ (1,756)
12 months or greater, Fair value	95,803
12 months or greater, Gross unrealized losses	$ (3,190)

Deferred Costs (Detail)

Deferred Costs (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2022
Deferred Costs [Abstract]
Deferred costs	$ 27,875,000		$ 27,875,000		$ 33,106,000
Amortization of deferred costs	5,000,000	$ 7,000,000	17,000,000	$ 19,000,000
Impairment losses recorded in relation to the costs capitalized	$ 0	$ 0	$ 0	$ 0

Property and Equipment, Net - C

Property and Equipment, Net - Components of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 82,545	$ 84,769
Less accumulated depreciation	(31,410)	(30,274)
Total property and equipment, net	51,135	54,495
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,040	3,040
Building
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,984	20,984
Land improvements and building improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,392	22,392
Equipment and computers
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,125	3,581
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	14,674	15,040
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,200	19,002
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 130	$ 730

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 1	$ 2	$ 5	$ 5

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Goodwill	$ 439,877		$ 439,877		$ 439,877
Amortization expense	$ 5,000	$ 5,000	$ 15,000	$ 14,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Details of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2022	Jan. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 177,042	$ 177,042
Accumulated amortization	(89,660)	(75,102)
Total	87,382	101,940
Existing technology
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	28,580	28,580
Accumulated amortization	(15,351)	(12,187)
Total	$ 13,229	$ 16,393
Remaining useful life (in years)	3 years 2 months 12 days	3 years 10 months 24 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 113,157	$ 113,157
Accumulated amortization	(47,404)	(38,829)
Total	$ 65,753	$ 74,328
Remaining useful life (in years)	6 years 3 months 18 days	7 years
Trade name/trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 13,900	$ 13,900
Accumulated amortization	(8,620)	(6,645)
Total	$ 5,280	$ 7,255
Remaining useful life (in years)	2 years	2 years 9 months 18 days
Other intangibles
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 21,405	$ 21,405
Accumulated amortization	(18,285)	(17,441)
Total	$ 3,120	$ 3,964
Remaining useful life (in years)	3 years 2 months 12 days	3 years 9 months 18 days

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Estimated Amortization Expense (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Remaining for 2023	$ 4,906
2024	19,459
2025	18,557
2026	14,147
2027	8,922
Thereafter	21,391
Total	$ 87,382	$ 101,940

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Payables and Accruals [Abstract]
Accrued commissions	$ 8,006	$ 8,556
Accrued bonus	3,321	4,677
Accrued vacation	6,068	5,546
Payroll tax payable	14,847	9,487
Accrued other compensation and benefits	8,023	5,568
Total accrued compensation and benefits	40,265	33,834
Accrued fees payable to Salesforce, Inc.	6,723	6,521
Taxes payable	5,596	9,743
Accrued third-party professional services subcontractors' fees	2,409	1,961
Other accrued expenses	18,132	17,884
Total accrued expenses and other current liabilities	$ 32,860	$ 36,109

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Assets
Short-term investments	$ 2,157,396	$ 1,238,064
U.S. treasury securities
Assets
Short-term investments	372,878	288,804
Commercial paper
Assets
Short-term investments	146,615	29,430
Corporate notes and bonds
Assets
Short-term investments	1,095,400	663,909
Certificates of deposit
Assets
Short-term investments	68,718	13,485
Asset-backed securities
Assets
Short-term investments	416,601	190,289
Foreign government bonds
Assets
Short-term investments	25,024	24,411
U.S. agency obligations
Assets
Short-term investments	32,160	27,736
Fair value, measurements recurring
Assets
Total financial assets	2,324,981	1,676,118
Fair value, measurements recurring | Money market funds
Assets
Cash equivalents:	117,017	428,411
Fair value, measurements recurring | U.S. treasury securities
Assets
Short-term investments	372,878	288,804
Fair value, measurements recurring | Commercial paper
Assets
Cash equivalents:	43,866
Short-term investments	146,615	29,430
Fair value, measurements recurring | Corporate notes and bonds
Assets
Cash equivalents:	6,673	5,853
Short-term investments	1,095,400	663,909
Fair value, measurements recurring | Certificates of deposit
Assets
Short-term investments	68,718	13,485
Fair value, measurements recurring | Asset-backed securities
Assets
Cash equivalents:		2,568
Short-term investments	416,601	190,289
Fair value, measurements recurring | Foreign government bonds
Assets
Short-term investments	25,024	24,411
Fair value, measurements recurring | U.S. agency obligations
Assets
Short-term investments	32,160	27,736
Fair value, measurements recurring | Foreign currency derivative contracts
Assets
Short-term investments	29	1,222
Fair value, measurements recurring | Level 1
Assets
Total financial assets	117,017	428,411
Fair value, measurements recurring | Level 1 | Money market funds
Assets
Cash equivalents:	117,017	428,411
Fair value, measurements recurring | Level 1 | U.S. treasury securities
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Commercial paper
Assets
Cash equivalents:	0
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Corporate notes and bonds
Assets
Cash equivalents:	0	0
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Certificates of deposit
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Asset-backed securities
Assets
Cash equivalents:		0
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign government bonds
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | U.S. agency obligations
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign currency derivative contracts
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 2
Assets
Total financial assets	2,207,964	1,247,707
Fair value, measurements recurring | Level 2 | Money market funds
Assets
Cash equivalents:	0	0
Fair value, measurements recurring | Level 2 | U.S. treasury securities
Assets
Short-term investments	372,878	288,804
Fair value, measurements recurring | Level 2 | Commercial paper
Assets
Cash equivalents:	43,866
Short-term investments	146,615	29,430
Fair value, measurements recurring | Level 2 | Corporate notes and bonds
Assets
Cash equivalents:	6,673	5,853
Short-term investments	1,095,400	663,909
Fair value, measurements recurring | Level 2 | Certificates of deposit
Assets
Short-term investments	68,718	13,485
Fair value, measurements recurring | Level 2 | Asset-backed securities
Assets
Cash equivalents:		2,568
Short-term investments	416,601	190,289
Fair value, measurements recurring | Level 2 | Foreign government bonds
Assets
Short-term investments	25,024	24,411
Fair value, measurements recurring | Level 2 | U.S. agency obligations
Assets
Short-term investments	32,160	27,736
Fair value, measurements recurring | Level 2 | Foreign currency derivative contracts
Assets
Short-term investments	$ 29	$ 1,222

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Fair Value Disclosures [Abstract]
Realized foreign currency gain	$ 2,000,000	$ 0	$ 10,000,000	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary Fair Value of Outstanding Derivative Instruments (Detail) - Foreign currency derivative contracts - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Derivatives, Fair Value [Line Items]
Notional amount of foreign currency derivative contracts	$ 50,039	$ 87,097
Fair value of foreign currency derivative contracts	$ 50,685	$ 85,876

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Outstanding Balance Sheet Hedges (Detail) - Foreign currency derivative contracts - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 29	$ 1,222
Accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities	$ (675)	$ 0

Income Taxes (Detail)

Income Taxes (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Income Tax Disclosure [Abstract]
Effective tax rates	19%	20.70%	20%	15.90%
Excess tax benefits in provision from employee stock plans	$ 1	$ 10	$ 10	$ 45

Deferred Revenue, Performance_2

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2022
Disaggregation of Revenue [Line Items]
Unbilled accounts receivable	$ 82,085		$ 82,085		$ 63,266
Subscription services
Disaggregation of Revenue [Line Items]
Recognition of deferred revenue	358,000	$ 296,000	638,000	$ 535,000
Unbilled accounts receivable	48,000		48,000		36,000
Professional services and other
Disaggregation of Revenue [Line Items]
Unbilled accounts receivable	$ 34,000		$ 34,000		$ 28,000

Deferred Revenue, Performance_3

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Performance Obligation Duration (Detail) - Subscription services $ in Millions	Oct. 31, 2022 USD ($)
Disaggregation of Revenue [Line Items]
Revenue expected to be recognized from remaining performance obligations	$ 1,189
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-11-01
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage	73%
Revenue, remaining performance obligation, recognition period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-11-01
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, recognition period

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Leases [Line Items]
Operating lease expense	$ 4	$ 3	$ 12	$ 10
Maximum
Leases [Line Items]
Operating leases, options to extend leases term	9 years		9 years
Finance leases, options to extend leases term	9 years		9 years

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021
Leases [Abstract]
Cash paid for operating lease liabilities	$ 11,320	$ 10,288
Operating lease right-of-use assets obtained in exchange for new operating lease liabilities	$ 13,937	$ 2,135

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Detail)	Oct. 31, 2022	Jan. 31, 2022
Operating Leases
Weighted Average Remaining Lease Term	6 years 9 months 18 days	6 years
Weighted Average Discount Rate	4.10%	3.70%

Leases- Maturities of Lease Lia

Leases- Maturities of Lease Liabilities (Detail) $ in Thousands	Oct. 31, 2022 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Remaining for 2023	$ 3,299
2024	9,405
2025	11,417
2026	9,499
2027	8,496
Thereafter	31,474
Total lease payments	73,590
Less imputed interest	(11,700)
Total	$ 61,890

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Oct. 31, 2022 USD ($) $ / shares shares	Jan. 31, 2022 USD ($) $ / shares shares
Number of shares
Options outstanding, Beginning balance (in shares) | shares	12,090,522
Options granted (in shares) | shares	3,178,165
Options exercised (in shares) | shares	(978,792)
Options forfeited/cancelled (in shares) | shares	(362,182)
Options outstanding, Ending balance (in shares) | shares	13,927,713	12,090,522
Options vested and exercisable (in shares) | shares	7,527,009
Options vested and exercisable and expected to vest thereafter (in shares) | shares	13,927,713
Weighted average exercise price
Options outstanding, Beginning balance (in usd per share) | $ / shares	$ 77.89
Options granted (in usd per share) | $ / shares	206.35
Options exercised (in usd per share) | $ / shares	30.59
Options forfeited/cancelled (in usd per share) | $ / shares	208.90
Options outstanding, Ending balance (in usd per share) | $ / shares	107.17	$ 77.89
Options vested and exercisable (in usd per share) | $ / shares	50.78
Options vested and exercisable and expected to vest thereafter (in usd per share) | $ / shares	$ 107.17
Weighted average remaining contractual term (in years), Options outstanding	5 years 2 months 12 days	4 years 7 months 6 days
Weighted average remaining contractual term (in years), Options vested and exercisable	2 years 9 months 18 days
Weighted average remaining contractual term (in years), Options vested and exercisable and expected to vest thereafter	5 years 2 months 12 days
Aggregate intrinsic value (in millions)
Options outstanding | $	$ 1,084	$ 1,964
Options vested and exercisable | $	913
Options vested and exercisable and expected to vest thereafter | $	$ 1,084

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Oct. 31, 2022 USD ($) $ / shares	Oct. 31, 2022 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock options granted	$ 380	$ 380
Intrinsic value of options exercised	$ 37	$ 165
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of options granted (in usd per share) | $ / shares	$ 85.55	$ 88.49
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of unvested stock (in years)		2 years 8 months 12 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of unvested stock (in years)		2 years 2 months 12 days
Unrecognized compensation cost related to unvested RSUs	$ 221	$ 221
Total intrinsic value, vested	$ 45	$ 137

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted (Detail) - Stock Options	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility, minimum	39%		37%	37%
Volatility, maximum	40%		40%	39%
Volatility		37%
Expected term (in years)	6 years 3 months	6 years 3 months		6 years 3 months
Risk-free interest rate, Minimum	2.90%	0.90%	1.90%	0.68%
Risk-free interest rate, Maximum	4.20%	1.30%	4.20%	1.30%
Dividend yield	0%	0%	0%	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)			6 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)			7 years

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Restricted Stock Unit (RSU) Activity (Detail) - Restricted Stock Units (RSUs)	9 Months Ended
	Oct. 31, 2022 $ / shares shares
Unreleased restricted stock units
Beginning balance (in shares) | shares	619,388
RSUs granted (in shares) | shares	1,495,425
RSUs vested (in shares) | shares	(702,297)
RSUs forfeited/cancelled (in shares) | shares	(84,017)
Ending balance (in shares) | shares	1,328,499
Weighted  average grant date fair value
Beginning balance (in usd per share) | $ / shares	$ 175.23
RSUs granted (in usd per share) | $ / shares	205.95
RSUs vested (in usd per share) | $ / shares	197.62
RSUs forfeited/cancelled (in usd per share) | $ / shares	199.28
Ending balance (in usd per share) | $ / shares	$ 196.43

Net Income per Share - Numerato

Net Income per Share - Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Weighted average shares used in computing net income per share, basic (in shares)	155,392	153,514	154,958	153,020
Net income per share, basic (in usd per share)	$ 0.70	$ 0.69	$ 1.93	$ 2.16
Reallocation as a result of conversion of Class B to Class A common stock:
Weighted average shares used in computing net income per share, diluted (in shares)	162,295	163,034	162,189	162,663
Net income per share, diluted (in usd per share)	$ 0.67	$ 0.65	$ 1.84	$ 2.03
Class A common stock
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income, basic	$ 98,151	$ 95,691	$ 270,666	$ 298,379
Weighted average shares used in computing net income per share, basic (in shares)	140,626	138,755	140,193	138,234
Net income per share, basic (in usd per share)	$ 0.70	$ 0.69	$ 1.93	$ 2.16
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic	$ 10,306	$ 10,178	$ 28,507	$ 31,915
Reallocation of net income to Class B common stock	0	0	0	0
Net income, diluted	$ 108,457	$ 105,869	$ 299,173	$ 330,294
Conversion of Class B to Class A common stock (in shares)	14,766	14,759	14,765	14,786
Effect of potentially dilutive common shares (in shares)	6,903	9,520	7,231	9,643
Weighted average shares used in computing net income per share, diluted (in shares)	162,295	163,034	162,189	162,663
Net income per share, diluted (in usd per share)	$ 0.67	$ 0.65	$ 1.84	$ 2.03
Class B common stock
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income, basic	$ 10,306	$ 10,178	$ 28,507	$ 31,915
Weighted average shares used in computing net income per share, basic (in shares)	14,766	14,759	14,765	14,786
Net income per share, basic (in usd per share)	$ 0.70	$ 0.69	$ 1.93	$ 2.16
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic	$ 0	$ 0	$ 0	$ 0
Reallocation of net income to Class B common stock	4,175	5,588	12,067	17,690
Net income, diluted	$ 14,481	$ 15,766	$ 40,574	$ 49,605
Conversion of Class B to Class A common stock (in shares)	0	0	0	0
Effect of potentially dilutive common shares (in shares)	6,903	9,520	7,231	9,643
Weighted average shares used in computing net income per share, diluted (in shares)	21,669	24,279	21,996	24,429
Net income per share, diluted (in usd per share)	$ 0.67	$ 0.65	$ 1.84	$ 2.03

Net Income per Share - Potentia

Net Income per Share - Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive (Detail) - shares	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Earnings Per Share [Abstract]
Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive (in shares)	5,022,968	1,105,478	4,363,631	869,044

Commitments and Contingencies (

Commitments and Contingencies (Detail) $ in Millions	Mar. 13, 2017 USD ($)
IQVIA Litigation Matter | Minimum
Long-term Purchase Commitment [Line Items]
Monetary damages	$ 200

Revenues by Product - Summary o

Revenues by Product - Summary of Total Revenues (Detail) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2022 USD ($) product_area	Oct. 31, 2021 USD ($)	Oct. 31, 2022 USD ($) product_area	Oct. 31, 2021 USD ($)
Disaggregation of Revenue [Line Items]
Number of product areas | product_area	2		2
Total revenues	$ 552,351	$ 476,111	$ 1,591,671	$ 1,365,278
Total subscription services
Disaggregation of Revenue [Line Items]
Total revenues	441,569	380,738	1,272,850	1,088,293
Commercial Solutions
Disaggregation of Revenue [Line Items]
Total revenues	239,276	223,183	703,356	649,156
R&D Solutions
Disaggregation of Revenue [Line Items]
Total revenues	202,293	157,555	569,494	439,137
Total professional services
Disaggregation of Revenue [Line Items]
Total revenues	110,782	95,373	318,821	276,985
Commercial Solutions
Disaggregation of Revenue [Line Items]
Total revenues	45,283	41,675	133,027	124,241
R&D Solutions
Disaggregation of Revenue [Line Items]
Total revenues	$ 65,499	$ 53,698	$ 185,794	$ 152,744

Information about Geographic _3

Information about Geographic Areas - Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2022	Oct. 31, 2021
Revenues by geography
Total revenues	$ 552,351	$ 476,111	$ 1,591,671	$ 1,365,278
North America
Revenues by geography
Total revenues	321,860	277,165	925,589	782,590
Europe
Revenues by geography
Total revenues	152,951	128,032	441,719	376,885
Asia Pacific
Revenues by geography
Total revenues	62,621	57,837	181,286	167,319
Middle East, Africa, and Latin America
Revenues by geography
Total revenues	$ 14,919	$ 13,077	$ 43,077	$ 38,484

Information about Geographic _4

Information about Geographic Areas - Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Oct. 31, 2022	Jan. 31, 2022
Long-lived assets by geography
Total long-lived assets	$ 51,135	$ 54,495
North America
Long-lived assets by geography
Total long-lived assets	43,069	45,625
Europe
Long-lived assets by geography
Total long-lived assets	5,552	6,135
Asia Pacific
Long-lived assets by geography
Total long-lived assets	902	1,335
Middle East, Africa, and Latin America
Long-lived assets by geography
Total long-lived assets	$ 1,612	$ 1,400